WALTHAM, Mass., Aug. 22, 2023 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) (“the Company”) today provided an update on injection kits supplied by Apellis and an update on the rare ...
We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Apellis is exclusively distributing injection kits with ...
Credit: Apellis. Syfovre is indicated for the treatment of geographic atrophy secondary to age-related macular degeneration. Apellis announced that as part of its investigation into real-world safety ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results